Skip to content
Home
Team
Healthcare
Patient-First Statement
Pipeline
Invest
Investor Hub
Corporate Governance
Shareholder Communications
News
Contact
Menu
Home
Team
Healthcare
Patient-First Statement
Pipeline
Invest
Investor Hub
Corporate Governance
Shareholder Communications
News
Contact
News
Search
Search
ASX News
General News
Publications
Thought Leadership
Uncategorised
All
January 29, 2023
Dosing Commences on EMD-RX5 Phase 3 Clinical Trial
January 18, 2023
Emyria in the Australian Financial Review on the future of psychedelics
January 12, 2023
Emyria receives $2m+ R&D tax incentive refund
December 22, 2022
Blog: Looking at 2022 and forward into 2023
December 14, 2022
Watch the video – Planet Microcap Showcase Presentation
December 6, 2022
December 7 & 8 Webinars
December 1, 2022
Emyria Company Update – December 2022
November 27, 2022
Emyria accepted into National Institutes of Health Preclinical Screening Platform for Pain program
November 23, 2022
Emyria Clinical E-Registry study into oral Medicinal Cannabis featured in the media
Load More